TY - JOUR
T1 - Who Is at Risk of Poor Mental Health Following Coronavirus Disease-19 Outpatient Management?
AU - Hüfner, Katharina
AU - Tymoszuk, Piotr
AU - Ausserhofer, Dietmar
AU - Sahanic, Sabina
AU - Pizzini, Alex
AU - Rass, Verena
AU - Galffy, Matyas
AU - Böhm, Anna
AU - Kurz, Katharina
AU - Sonnweber, Thomas
AU - Tancevski, Ivan
AU - Kiechl, Stefan
AU - Huber, Andreas
AU - Plagg, Barbara
AU - Wiedermann, Christian J
AU - Bellmann-Weiler, Rosa
AU - Bachler, Herbert
AU - Weiss, Günter
AU - Piccoliori, Giuliano
AU - Helbok, Raimund
AU - Loeffler-Ragg, Judith
AU - Sperner-Unterweger, Barbara
N1 - Copyright © 2022 Hüfner, Tymoszuk, Ausserhofer, Sahanic, Pizzini, Rass, Galffy, Böhm, Kurz, Sonnweber, Tancevski, Kiechl, Huber, Plagg, Wiedermann, Bellmann-Weiler, Bachler, Weiss, Piccoliori, Helbok, Loeffler-Ragg and Sperner-Unterweger.
PY - 2022
Y1 - 2022
N2 - BACKGROUND: Coronavirus Disease-19 (COVID-19) convalescents are at risk of developing a de novo mental health disorder or worsening of a pre-existing one. COVID-19 outpatients have been less well characterized than their hospitalized counterparts. The objectives of our study were to identify indicators for poor mental health following COVID-19 outpatient management and to identify high-risk individuals.METHODS: We conducted a binational online survey study with adult non-hospitalized COVID-19 convalescents (Austria/AT: n = 1,157, Italy/IT: n = 893). Primary endpoints were positive screening for depression and anxiety (Patient Health Questionnaire; PHQ-4) and self-perceived overall mental health (OMH) and quality of life (QoL) rated with 4 point Likert scales. Psychosocial stress was surveyed with a modified PHQ stress module. Associations of the mental health and QoL with socio-demographic, COVID-19 course, and recovery variables were assessed by multi-parameter Random Forest and Poisson modeling. Mental health risk subsets were defined by self-organizing maps (SOMs) and hierarchical clustering algorithms. The survey analyses are publicly available (https://im2-ibk.shinyapps.io/mental_health_dashboard/).RESULTS: Depression and/or anxiety before infection was reported by 4.6% (IT)/6% (AT) of participants. At a median of 79 days (AT)/96 days (IT) post-COVID-19 onset, 12.4% (AT)/19.3% (IT) of subjects were screened positive for anxiety and 17.3% (AT)/23.2% (IT) for depression. Over one-fifth of the respondents rated their OMH (AT: 21.8%, IT: 24.1%) or QoL (AT: 20.3%, IT: 25.9%) as fair or poor. Psychosocial stress, physical performance loss, high numbers of acute and sub-acute COVID-19 complaints, and the presence of acute and sub-acute neurocognitive symptoms (impaired concentration, confusion, and forgetfulness) were the strongest correlates of deteriorating mental health and poor QoL. In clustering analysis, these variables defined subsets with a particularly high propensity of post-COVID-19 mental health impairment and decreased QoL. Pre-existing depression or anxiety (DA) was associated with an increased symptom burden during acute COVID-19 and recovery.CONCLUSION: Our study revealed a bidirectional relationship between COVID-19 symptoms and mental health. We put forward specific acute symptoms of the disease as "red flags" of mental health deterioration, which should prompt general practitioners to identify non-hospitalized COVID-19 patients who may benefit from early psychological and psychiatric intervention.CLINICAL TRIAL REGISTRATION: [ClinicalTrials.gov], identifier [NCT04661462].
AB - BACKGROUND: Coronavirus Disease-19 (COVID-19) convalescents are at risk of developing a de novo mental health disorder or worsening of a pre-existing one. COVID-19 outpatients have been less well characterized than their hospitalized counterparts. The objectives of our study were to identify indicators for poor mental health following COVID-19 outpatient management and to identify high-risk individuals.METHODS: We conducted a binational online survey study with adult non-hospitalized COVID-19 convalescents (Austria/AT: n = 1,157, Italy/IT: n = 893). Primary endpoints were positive screening for depression and anxiety (Patient Health Questionnaire; PHQ-4) and self-perceived overall mental health (OMH) and quality of life (QoL) rated with 4 point Likert scales. Psychosocial stress was surveyed with a modified PHQ stress module. Associations of the mental health and QoL with socio-demographic, COVID-19 course, and recovery variables were assessed by multi-parameter Random Forest and Poisson modeling. Mental health risk subsets were defined by self-organizing maps (SOMs) and hierarchical clustering algorithms. The survey analyses are publicly available (https://im2-ibk.shinyapps.io/mental_health_dashboard/).RESULTS: Depression and/or anxiety before infection was reported by 4.6% (IT)/6% (AT) of participants. At a median of 79 days (AT)/96 days (IT) post-COVID-19 onset, 12.4% (AT)/19.3% (IT) of subjects were screened positive for anxiety and 17.3% (AT)/23.2% (IT) for depression. Over one-fifth of the respondents rated their OMH (AT: 21.8%, IT: 24.1%) or QoL (AT: 20.3%, IT: 25.9%) as fair or poor. Psychosocial stress, physical performance loss, high numbers of acute and sub-acute COVID-19 complaints, and the presence of acute and sub-acute neurocognitive symptoms (impaired concentration, confusion, and forgetfulness) were the strongest correlates of deteriorating mental health and poor QoL. In clustering analysis, these variables defined subsets with a particularly high propensity of post-COVID-19 mental health impairment and decreased QoL. Pre-existing depression or anxiety (DA) was associated with an increased symptom burden during acute COVID-19 and recovery.CONCLUSION: Our study revealed a bidirectional relationship between COVID-19 symptoms and mental health. We put forward specific acute symptoms of the disease as "red flags" of mental health deterioration, which should prompt general practitioners to identify non-hospitalized COVID-19 patients who may benefit from early psychological and psychiatric intervention.CLINICAL TRIAL REGISTRATION: [ClinicalTrials.gov], identifier [NCT04661462].
UR - https://www.scopus.com/pages/publications/85127611227
U2 - 10.3389/fmed.2022.792881
DO - 10.3389/fmed.2022.792881
M3 - Article
C2 - 35360744
SN - 2296-858X
VL - 9
SP - 792881
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 792881
ER -